A new treatment for relapsed and refractory multiple myeloma (RRMM) is on the way. The European Medicines Agency (EMA) has recommended granting a licence to ciltacabtagene autoleucel (Carvykti) for the treatment of patients with RRMM who have received four or more prior lines of therapy, including a proteasome inhibitor, an...